Spero Therapeutics, Inc. (SPRO)
1.165
-0.02
(-2.10%)
USD |
NASDAQ |
Oct 07, 16:00
1.165
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -2.79K% |
| December 31, 2025 | 79.48% |
| September 30, 2025 | -242.2% |
| June 30, 2025 | -14.40% |
| March 31, 2025 | -271.3% |
| December 31, 2024 | -223.3% |
| September 30, 2024 | -219.3% |
| June 30, 2024 | -296.9% |
| March 31, 2024 | -301.4% |
| December 31, 2023 | 71.27% |
| September 30, 2023 | -13.71% |
| June 30, 2023 | -1.51K% |
| March 31, 2023 | -1.79K% |
| December 31, 2022 | 57.75% |
| September 30, 2022 | -1.08K% |
| June 30, 2022 | -3.20K% |
| March 31, 2022 | -13.29K% |
| December 31, 2021 | -11.42K% |
| Date | Value |
|---|---|
| September 30, 2021 | -3.18K% |
| June 30, 2021 | -881.9% |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | -474.0% |
| June 30, 2020 | -1.01K% |
| March 31, 2020 | -1.37K% |
| December 31, 2019 | -688.3% |
| September 30, 2019 | -381.6% |
| June 30, 2019 | -609.9% |
| March 31, 2019 | -65.72% |
| December 31, 2018 | -626.4% |
| September 30, 2018 | -1.59K% |
| June 30, 2018 | -2.15K% |
| March 31, 2018 | -923.2% |
| December 31, 2017 | -1.40K% |
| September 30, 2017 | -1.65K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -- |
| Fortress Biotech, Inc. | 3.22% |
| Kura Oncology, Inc. | -327.3% |
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 17.13% |
| Return on Assets | 12.43% |
| Return on Invested Capital | 16.06% |
| Return on Net Operating Assets | 62.88% |